Transform how you analyse drug development risk
With the only transparent analysis of drug development risk at the product level.
Breakthrough offering combines the power of machine learning with the transparency of Evaluate’s renowned analytical approach for the most accurate analysis of drug…
The report, published today, analyses stock and market performance, M&A and the financing landscape during the first half of 2019
“EvaluatePharma® World Preview 2019, Outlook to 2024” explores growth drivers, growth brakes and top industry performers.
Annual “EvaluatePharma Orphan Drug 2018 Report” sees Orphan drugs capture a fifth of worldwide prescription sales by 2024 as sales grow to $262bn.
EP Vantage releases its annual analysis of sector performance: Pharma, Biotech and Medtech 2017 in Review.
EP Vantage’s Annual Pharma and Biotech Preview explores what’s in store for 2018.
EvaluateMedTech Report Launches in Conjunction with The MedTech Conference.
EP Vantage Releases Half-Year Reviews of Pharma & Biotech and Medtech Performance.
Latest growth forecasts show optimism surrounding new therapies coming to market counterbalanced by more stringent pricing policy enforcement.
New Case Studies Highlight Niche Patient Population Identification and Analysis for Enhanced Portfolio Decision-making Using Evaluate’s Epi Analyzer
Fall comes as average cost of developing new drugs totals $4bn over the last 10 years.
Annual Pharma & Biotech World Preview Report to Launch at Bio 2017